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ABSTRACT

SURVIVAL-RELATED CLUSTERING OF CANCER PATIENTS BY
INTEGRATING CLINICAL AND BIOLOGICAL DATASETS

Xinming Wei

Marquette University, 2020

Subtype-based treatments and drug therapies are essential aspects to be considered
in cancer patients' clinical trials to provide appropriate personalized therapies. With the
advancement of the next-generation sequencing technology, several computational models,
integrating genomic and transcriptomic datasets (i.e., multi-omics) in the prediction of
subtype-based classification in cancer patients, were emerged. However, integration of the
prognostic features from the clinical data, related to survival risks with the multi-omics
datasets in the prediction of different subtypes, is limited and an important research area to
be explored. In this study, we proposed a data integration pipeline with the prognostic
features from the clinical data and multi-omics datasets to predict the survival-risk-based
subtypes in Kidney Renal Clear Cell Carcinoma (KIRC) patients from The Cancer Genome
Atlas (TCGA) database. Firstly, we applied an unsupervised clustering algorithm on
KIRC patients and clustered them into two survival-risk-based subgroups, i.e., subtypes.
Then, using the clustering-based subtype labels as class labels for cancer patients, we
trained a supervised classification model to determine the class label of un-labeled
patients.
In our clustering step, we applied multivariate Cox Proportional Hazard (Cox-PH)
model to select the survival-related prognostically significant features (p-value < 0.05)
from the patients’ multivariate clinical data. Then, we used the Silhouette Coefficient to
determine the optimal number (k) of the clusters. In our classification step, we integrated
high dimensional multi-omics datasets with three different data modalities (such as gene
expression, microRNA expression, and DNA methylation). We utilized a dimensionreduction approach, followed by a univariate Cox-PH for each reduced data modality with
patients’ survival status. Then, we selected the survival-related reduced-omics-features in
our classification model. In this step, we applied a supervised classification method with
10-fold cross-validation to check our survival-based subtype prediction accuracy. We
tested multiple machine learning and deep learning algorithms in different steps of the
pipeline for clustering (K-means, K-modes and, Gaussian mixture model), dimensionreduction (Denoising Autoencoder and Principal Component Analysis) and classification
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(Support Vector Machine and Random Forest) purposes. We proposed an optimized model
with the highest survival-specific-subtype classification accuracy as the final model.
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CHAPTERS

I. INTRODUCTION

A. General Introduction

Cancer is a complex genetic disease that is the most intractable medical and health
problem in the world [1]. With the advances in high throughput sequencing technologies,
nowadays, we could collect much data to study the diagnosis and prognosis of cancer.
Cancer can be divided into different subtypes according to cell morphology and cell period;
different subtypes of cancer might have different survival characteristics in addition to
different molecular expressions. For decades, one of the most popular areas in cancer
studies has been to explore patterns of molecular data sets to cluster and treat different
subtypes of specific cancer. There are several studies on clustering cancer patients,
integrating multi-omics data, specifically, gene expression, DNA methylation, and micro
RNA (miRNA) expression [2, 3, 24]. However, studies on clustering cancer patients with
prognostic variables present in the clinical datasets are limited. Therefore, we propose a
clustering model to apply clinical data that was survival-related to cluster cancer patients,
followed by a classification approach using multi-omics datasets to determine the cluster
label of the new cancer patients.
In our clustering step, we applied a multivariate Cox-PH model to select the
survival-risk-related prognostically significant clinical features and determined the
survival-related clusters. We tested multiple clustering algorithms, such as K-means, Kmodes, and Gaussian mixture model (See Chapter I.C).
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In our classification step, we integrated the high dimensional multi-omics datasets
with three different data modalities (such as gene expression, miRNA expression, and DNA
methylation). We utilized a dimension-reduction approach, followed by a univariate CoxPH for each reduced data modality with patients’ survival status.
To reduce the dimension of the multi-omics datasets, we tested different algorithms,
such as denoising autoencoder [5], Principal components analysis (PCA), and PCA-surv
[6] (See Chapter I.C). For the classification purpose, we tested two different machine
learning methods, such as support vector machine (SVM) and random forest [7] (See
chapter I.C).
Among these different algorithms, we selected K-modes for clustering, PCA-surv
for dimension reduction, and SVM for classification, respectively, that produce an
optimized model in terms of classification accuracy of our survival- specific subtypes
prediction.
We tested our pipeline on Kidney Renal Clear Cell Carcinoma (KIRC) cancer from
the TCGA database [8]. We integrated KIRC clinical data along with gene expression,
DNA methylation, and miRNA expression datasets in the pipeline (See Chapter III.B for
details). The datasets were downloaded using the TCGAbiolinks package in the R
programming language [9].
The purpose of this work was to establish the importance of applying clinical data
in the prediction of cancer subtypes, along with multi-omics datasets. We also assessed the
predicted survival-related subtypes under different clinical conditions. Our results
suggested that cancer stages of the patients play a more prominent role in clustering
analysis than patients’ age.
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B. Research Problems

Research by integrating multi-omics datasets have been increasingly applied in the
diagnosis and prognosis of cancer [24]. However, integration of the prognostic features
from the clinical data, related to survival risks with the multi-omics datasets in the
prediction of different subtypes, is limited and an important research area to be explored.
Therefore, in this study, we proposed a clustering model applying clinical data that was
survival-related to cluster cancer patients, followed by a classification approach using
multi-omics datasets to predict the cluster label of new patients. We utilized Cox-PH to
find prognostic clinical variables and clustered cancer patients based on these variables.
After integrating multi-omics datasets, we used multi-omics features to determine the
cluster label of un-labeled patients.
C. Definition and Explanation of Key Terminology

TCGA KIRC data: The Cancer Genome Atlas is a database that provides multiple
cancers patients’ genomic and clinical data [10, 14]. Large-scale genome sequencing of
over 10,000 samples in more than 30 types of cancers was performed. The KIRC data is
one of those datasets to record the data of kidney renal clear cell carcinoma (KIRC) patients.
Univariate Cox-PH: Univariate analysis using the Cox regression technique is
applied when there is a single, independent, potentially survival-related variate. The
variables that are related to survival are selected respectively as independent features.
Multivariate Cox-PH: Multivariate analysis using the Cox regression technique is
applied when there are multiple, potentially survival-related covariates [11]. DR Cox
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proposed it in 1984, and the concept of multivariate Cox-PH was proposed in 1996 [40].
This concept can be applied to select survival-related data from multiple variables.
K-means: The K-means is an iterative clustering algorithm [41]. First, K data points
are chosen randomly as cluster centers. Each data is divided into clusters around the center
at the minimum distance. In each iteration, the distance between the sample and the center
is recalculated, and the sum of distances to the center reaches the minimum at the final
stage.
GMM: The Gaussian mixture model (GMM) is a probabilistic model that assumes
that all the data points are generated from a mixture of Gaussian distributions. In
probabilistic modeling, the probability distribution over all the discovered clusters is
inferred for each observation. [42].
K-modes: The K-modes algorithm is an extension of the K-means algorithm. It is a
multi-iteration clustering algorithm. It is widely used when applying categorical data in
clustering, which is not available in K-means [43]. For example, in our case, genders, races,
cancer stages in the clinical data, are such categorical variables that are not available in Kmeans to compute the distance. K-modes uses dissimilarity measure as the distance
measure for clustering. First, K samples were chosen randomly as cluster centers, and each
sample was divided into clusters around the center at the minimum number of mismatched
features. The fewer the mismatched features between the sample and the cluster center
indicates the smaller the distance between them. Through multiple iterations, the total
number of mismatched values between the sample and the cluster center is minimized to
determine which cluster the samples belong to.
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Rank normalization: Rank normalization is a pre-processing method on data for
quantile normalization. It is based on the premise of not losing parameter information and
avoiding the impact of specific extreme values on the entire data. The normalization
replaced each observation with a ranking in the matrix, divided by the total number of
features [12, 13]. We applied the rank normalization on the gene expression, DNA
methylation, and miRNA expression data matrices downloaded from TGCA.
Denoising autoencoder: The denoising autoencoder can reduce the noise in the
original data by reconstructing the input data. The function of the denoising autoencoder
is to learn from the original data with the superimposed noise. The features it learns can be
decoded to the output almost the same as the original input data. The obtained feature from
the hidden nodes is robust by reducing the noise in the data from extreme values and
learning the same feature value.
PCA: Principal Component Analysis (PCA) is a statistical method to reduce the
dimension of data that contains sufficient information. By transforming data that may have
a linear correlation into linearly uncorrelated components, all the components selected
according to the proportion of variance are called principal components. A few principal
components reveal the internal structure among multiple variables with a threshold of with
the Proportion of Variance. By performing this step, a few principal components are
derived from the original variables. They retain as much information as possible from the
original variables and are not linearly correlated.
PCA-surv: The components obtained by principal component analysis are utilized
in survival analysis. By using Cox-PH, components related to survival were selected as
new features.
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SVM: Support Vector Machine (SVM) is a widely used classification model. It
divides the feature values in space by the maximum distance; its decision method uses
maximum-margin hyperplane to maximize the distance between the features. SVM can be
used for nonlinear classification by kernel method, one of the conventional kernel-learning
methods [7, 14].
RF: Random Forest (RF) is a classification model based on the decision tree.
Essentially, the random forest is an integrated learning model that uses decision trees for
multiple iterations. Through multiple decision combinations to solve the prediction
problem brought by every single decision tree, the model can generate multiple classifiers,
each of which can independently predict and learn.
D. Context of Research Study within the Greater Discipline

The future challenge of bioinformatics is to comprehensively understand the
systematic role of molecular information, which can be achieved by studying multi-omics
data simultaneously. Integrating multiple types of data of cancer patients into deep-learning
algorithms and other analysis algorithms may resolve our current knowledge gap in
molecular mechanisms, the interaction between genes and the environment, and the vertical
effects of cancer development [15, 16]. Multi-omics data integration methods can improve
the understanding of genetic diseases and cancer and may lead to new strategies for early
diagnosis, prognosis, and treatment of human diseases. At present, there are many studies
on multi-omics, and as well as comprehensive methods and frameworks in integrative
analyses [18, 19, 20]. Moreover, Sun and Hu summarized the analysis methods of highthroughput multi-omics data. They provided an updated, comprehensive method and
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framework to integrate genome, epigenome, transcriptome, proteome, and metabolome
data into the emerging field of multi-omics research in human diseases [37]. These findings
reveal the diversity of biological systems and can identify biomarkers and gene loci to a
certain extent. The expressions of multi-omics data are similar, and it is possible to discover
similarities by integrating features through deep-learning algorithms. High-throughput
experimental methods can provide various datasets to study multi-omics data
simultaneously.
II. HYPOTHESIS (THEORY)

A. Brief Overview of Theoretical Foundations Utilized in the Study

Diseases are expressed differently at different stages and in different populations
[21]. In survival analysis, the samples by integrating prognostic clinical data of different
populations may have patterns in different clusters. For example, different age ranges,
different stages of the disease, different races, different expression levels of physical
indicators are factors that affect prognostic characteristics. Therefore, clinical data related
to survival were selected through Cox-PH analysis, and these variables were used for
clustering samples into different survival clusters with survival differences.
On the other hand, multi-omics data, such as gene expression data, DNA
methylation data, microRNA expression data also have similar survival-related
characteristics. In previous studies, Hao et al. proved that patients could be clustered by
integrating multi-omics data by conducting different dimensionality reduction processing
and extracting corresponding features [22].
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We integrated the multi-omics data into low-dimensional, representative, new
features related to survival, classifying them according to the previous clustering, and
verifying the reliability of clustering based on prognostic clinical data. Since many
previous and future studies cluster based on multi-omics data, there is evidence to verify
clustering results by multi-omics data [23].
Although it is not always possible to achieve complete agreement by comparing the
two types of data, we expect to find correlations between prognostic clinical data and multiomics data, such as gene expression, through this verification process. Through further
exploration and improvement of the algorithm, it will better handle the clustering,
diagnosis, treatment, and prognosis of cancer patients and provide a more comprehensive
understanding of the analysis of cancer.
B. Literature Reviewed, Discussed and Applied

Overview of cancer
Many cancers (i.e., BRCA, KIRC, AML, etc.) can be divided into several subtypes
based on characteristics of the development stage and cancer cell morphology. Therefore,
different cancer subtypes may have different levels of gene expression or survival patterns.
In a recent study, Rappoport et al. have given a comprehensive comparison among different
methods (i.e., iCluster, SNF, rMKL-LPP, K-means) to cluster cancer patients [24].
Similarly, we can cluster cancers into subtypes based on different survival characteristics
and look for associations between specific groups and different subtypes.
Integrating prognostic clinical data
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As early as 1976, Solberg et al. began to explore the use of cancer clinical trial data
to perform cluster analyses on patients [26]. They found that the clustering results based
on the results of clinical trials had a steady correspondence with the results of the biopsy.
Studies have also shown that gene expression analysis can be used to predict the clinical
outcome of cancer [27], which indicates that the clustering features of genomics are related
to clinical data and prognostic signatures. In the research of other diseases, cluster analysis
of clinical data is also used to identify the subgroup of fibromyalgia [28]. However, we
proposed a pipeline based on Poirion et al. in 2018 while not widely discussed to cluster
patients related to survival analysis, especially the clustering results derived from clinical
data related to survival.
Survival analysis
The predictive model of survival time is a standard tool for cancer prognosis
survival analysis [29], while the Cox-PH model is the most commonly used survival
prediction model for cancer-survival prediction [4]. The survival risk and actual survival
time of each patient can be determined through different performance indicators and
clustering different indicators can find the consistency of the survival risk and survival time.
We clustered the patients to determine their survival risk subtypes according to their
survival status and time.
Research has shown that in the field of deep learning, identifying complex multiomics data interactions related to patient survival time and risk at the molecular level is
important. It is not only for the development of new diagnostic and therapeutic methods
but also for accurate survival predictions [31]. Hao et al. developed a new path-based sparse
deep neural network (PASNet) for cancer survival analysis. Besides, integrating survival-
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related clinical data from cancer samples is expected to improve cancer survival prediction
and diagnosis. Specifically, the integration of multi-omics data and clinical data can be
used for survival prediction and diagnosis in cancer research. It also provides an in-depth
understanding of cancer and multi-omics data by comparing the performance of the current
state-of-the-art model with TCGA cancer data and statistically evaluating the outstanding
performance. There is also relevant biological literature that supports the biological
interpretation of the PASNet.
Furthermore, the integration of multi-omics data in another study by Hao et al. have
demonstrated an understanding of the complex mechanisms of human genetic diseases and
cancer and provides excellent help for precise medication and treatment [22]. In this study,
they proposed a deep neural network based on genes and pathways for multi-omics data
integration (MiNet) to predict cancer-survival outcomes. The study integrates multi-omics
regulation(i.e., genomics, epigenomics, and transcriptomics) in a neural network based on
genes and pathways. This provides a specific classification model for 10-fold crossvalidation in the survival-related analysis.
A recent study [32] described the challenges of deep learning in cancer survival
analysis, such as dealing with different types of multi-omics data and hugely different
sample sizes. Improving the deep-learning model will integrate multiple types of data,
predict the survival results and survival time of samples, and maximize the correlation
among multi-omics data, clinical data, and survival analysis. This research can provide a
better perspective on cancer drug treatment and survival analysis [25].
Integrating multi-omics data
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Human diseases and cancer involve the influence of multi-omics interaction and
expression and are affected by environmental factors, as well. Many studies have focused
on multi-omics research [37]. At the molecular level (i.e., genetics, epigenetics, and
transcriptomics), recent technological advances have allowed integrated analysis of the
human genome, epigenome, and metabolome at the population level. Complex and
dynamic molecular networks are involved in human diseases. High-throughput technology
enables omics research to allow us to obtain evidence of disease diagnosis in different
omics data. However, single omics research can only provide a limited understanding of
the molecular mechanisms of cancers.
In recent years, the diagnosis of cancer has not only been limited to a single omic
study, while the diagnosis of a single omic can only provide limited information of the
disease. Multi-omics research has gradually been applied to the diagnosis and treatment of
cancer. However, multi-omics research applied to prognosis work is still minimal. In a
recent study [30], somatic mutations, DNA copy number, DNA methylation, gene
expression, and miRNA expression were used in prognostic studies of multi-omics features.
Zhu et al. found that mRNA and miRNA expression profiles are the best in prognosis and
diagnosis, followed by DNA methylation. They also stated that kernel machine-learning
methods always outperform prognostic signatures. In another study [33], although nothing
was summarized about disease clustering and prediction, a framework for the biological
and functional roles of multi-omics was built. In addition to genomics, transcriptomics,
epigenomics, proteomics, and metabolomics data have also been discussed. However,
multi-omics research can broaden the complexity of cancer research and improve the
accuracy of cancer diagnosis and prognosis.
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The complexity of tumor genes has proven to be an enormous challenge to the
diagnosis and prognosis of cancer. Single omics cannot provide a complete and
comprehensive evaluation basis. As the most commonly used genomic and transcriptomics
study in prognosis, tens of thousands of genetic variations, including SNPs and DNA
copies, are linked to various human diseases through GWAS [34]. In genomic and
transcriptomics studies, next-generation sequencing technology [36], including RNA-seq
[35] methods, is the most commonly used means of providing genetic variation. In the
evaluation of cancer prognosis, the epigenetic group, which refers to heritable molecular
modification and mainly includes DNA methylation, is also a critical evaluation
characteristic [3].
As far as GWAS is concerned, although tens of thousands of SNPs have been
identified for disease diagnosis and identification, the functional meaning and mechanism
of related loci are still unclear. Besides, mutations in the genome alone cannot predict
disease risk throughout the disease cycle [38]. Based on the success of single-omics
discovery research, a multi-omics approach integrates data obtained from different omics
to understand their interactions and impact on the disease process. Sun et al, summarized
the main omics methods available in population studies and reviews the deep-learning
methods that integrate multi-omics layers, which provide a better perspective for gene
discovery and functional analysis of human diseases.
In another study, Zhang et al. clustered patients with high-risk neuroblastoma
according to clinical information and prognostic results [39]. However, there is still a lack
of survival risk analysis for high-risk neuroblastoma. To make up for the gap in survivalrisk analysis, they used a deep-learning algorithm, autoencoder, to compare with PCA to

[13]

understand clustering based on multi-omics data integration. They used the K-means
clustering method to identify two with distinct survival subtypes of risk differences. The
results showed that with the methods and datasets they examined, classification based on
autoencoders was superior. Zhang et al. also verified the feature selection of autoencoder
for high-risk neuroblastoma through two independent data sets, which helped to control
survival risk better and proved that deep-learning-based algorithms are very useful in
multi-omics integration.
C. Hypotheses and Justifications Tied to Prior Sections or Statements

By studying the previous research results, we understand that the integration of
multi-omics research plays an important role in the clustering of cancer patients. We expect
the integration of multi-omics data to verify the characteristics of survival analysis in
clinical data. We hypothesize that there are similar survival characteristics in clinical data
and multi-omics data. We selected variables closely related to survival through Cox-PH,
clustered the cancer samples into different survival risks subtypes, and then used the
integrated multi-omics data in the classification model to verify our clustering results. We
tested multiple machine learning and deep learning algorithms in different steps of the
pipeline for clustering, dimension-reduction, and classification purposes and proposed an
optimized model with the highest survival-specific-subtype classification accuracy as the
final model.
D. Theoretical Assumptions and Limitations

Based on previous studies and known theories, we assumed that the clinical data of
cancer patients would show specific characteristics related to survival and particular
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clustering phenomenon in different ages, disease stages, and other clinical data. The
survival-related clustering is somewhat similar in the integration of multi-omics data, such
as gene expression, DNA methylation, and microRNA expression.
It is very promising to obtain high compliance results by using multi-omics data to
verify the clustering results based on clinical data. Meanwhile, the results may not be high
consistency between clinical and biological datasets. The processing of multi-omics data
may have more aspects to improve. Therefore, based on the existing processing methods
and algorithms, the results verified by two kinds of data could be improved in advance.
III. METHODS

A. Introduction and General Description, Study Methods, and Study Design

In this project, we clustered cancer patients by integrating survival-related clinical
data to predict survival-specific clusters. The multivariate Cox-PH algorithm was used to
select variables significant to survival, meaning p-values are less than 0.05. By applying
those variables, multiple clusters can be predicted by various clustering methods, such as
K-means, K-modes, and GMM. Thus, we can cluster patients into different groups based
on their survival characteristics. Classification is done by integrating multi-omics datasets,
such as gene expression, DNA methylation, and microRNA expression.
Gene expression, DNA methylation, and miRNA expression data are enormous
datasets. They contain a large amount of information. Moreover, studying on such datasets
is very meaningful and promising to obtain useful information for diagnosis. However,
analyzing such a large amount of data requires much time and large calculation memory.
Through dimensionality reduction of the data sets, we can reduce the required storage space,
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speed up the calculation (such as in machine learning algorithms), remove redundant
features, and avoid overfitting. Lower dimensions require less calculations. Lower
dimensions data can be applied to the algorithms that are not suitable for high dimensions
data. There are many alternative methods available to reduce the dimension of the multiomics data. For example, denoising autoencoder (DAE) is a neural network that can apply
multiple layers and multi-omics datasets as original parameter settings. Moreover, PCA is
also an alternative method for dimension reduction. By using these algorithms, we could
reduce the dimensions of the massive amounts of data in mRNA, methylation, and miRNA
datasets from TCGA. For DAE, by using an autoencoder, we built a network with 100
hidden nodes (h = 100) to limit every single omic data to 100 new features. To use the PCA
method for dimension reduction, components with Proportion of Variance greater than 0.01
were selected. On the other hand, an alternative option was to select components from the
PCA method as new features that were survival-related, while p-values were less than 0.01
by using the Cox-PH analysis, which means there is a probability of 0.01 that the features
are not related to survival.
For each omic, we built an individual model to select new features related to
survival. For this step, individual Cox-PH was used to select those features related to
survival from new matrices produced by dimension-reduction methods. The patients were
then classified with these features by the clusters inferred to clinical survival-related
variables. K-fold cross-validation was utilized for classification by using SVM with linear
kernels and RF; and thus, to build a supervised classification model to verify whether there
were common patterns with clinical data. Accuracy, specificity, and sensitivity were used

[16]

to evaluate the results. A confusion matrix was used to combine these parameters to have
a comprehensive view of the results.
B. Datasets

We obtained the three omics datasets and a clinical dataset, including mRNA,
miRNA, and DNA methylation, and clinical data of TCGA KIRC by using the
TCGAbiolinks package in the R programming tool. In this project, 534 samples in clinical
data were also obtained from TGCA for clustering. 317 samples of KIRC were obtained
from TCGA for integrating and pre-processing. For mRNA expression data, we used
Fragments Per Kilobase of transcript per Million mapped reads (FPKM) produced by highthroughput sequencing data (HT-seq) platform. For DNA methylation, the average
methylation value of all the CpG sites was calculated from the Illumina Human
Methylation 450K platform. For miRNA expression sequencing data, we used reads per
million (RPM) normalized quantification values from British Columbia Genome Sciences
Centre (BCGSC) miRNA profiling of the miRNA expression quantification dataset. For
clinical data, we used clinical supplement data from TCGA KIRC projects. In 317 samples
in multi-omics data and 534 samples in clinical data, we finally selected the overlapped
samples, which contained 315 samples, with all types of data, including multi-omics data
and clinical data.
C. Samples in TCGA Project

The TCGA project was launched in the United States in 2005 and aimed to apply
genomic analysis techniques to study genomic changes in cancer. Large-scale genome
sequencing of over 10,000 samples in more than 30 types of cancers was performed. It is
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especially valuable that these samples have very detailed prognostic follow-up information
[10].
TCGA contains the following data: 1) Clinical sample information: Biospecimen,
Clinical; and 2) Sequencing data: The five methods of RNA-Seq, WXS, miRNA-Seq,
Genotyping Array, and Methylation Array are mainly used to analyze samples.
RNA-Seq data in TCGA is transcriptome sequencing. The transcriptome data on
TCGA uses full transcriptome sequencing, which contains various non-coding RNAs, so
the generally downloaded RNA-Seq data contains lncRNA, mRNA, pseudogenes, etc.
RNA-Seq quantitative expression data is currently available for public download in three
forms: HT-Seq-FPKM, HT-Seq-UQ-FPKM, HT-Seq-Counts, where FPKM is used to
measure the abundance of transcript expression, counts is counted on a gene in the reads
sequenced, and UQ-FPKM is standardized FPKM by the upper quartile.
miRNA is a type of non-coding single-stranded RNA molecule that is
approximately 22 nucleotides (nt) in length and is encoded by an endogenous gene. It is a
significant type of non-coding small RNA in biology, and the regulation of organisms;
about one-third of genes in humans are regulated by miRNA [44]. TCGA provided
miRNA-Seq sequencing data results, using a database of miRBase v21. There are two main
types of data currently available for public download: miRNA Expression Quantification
and Isoform Expression Quantification, where the Isoform Expression Quantification data
contains mature miRNA. TCGA provides quantitative data in Counts and FPKM formats.
In miRNA, pre-miRNA is a precursor miRNA, about 70–90 bases in length; premiRNA is digested by Dicer enzyme and becomes mature miRNA about 20–24 nt long.
miRNA is generally mature miRNA, about 20–24 nt in length, developed from various
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precursor miRNAs. The relationship between miRNA and target genes is, generally,
miRNA regulates target genes and reduces the expression of the target genes.
DNA methylation is a reversible and inheritable process that can lead to changes in
chromatin structure, DNA conformation, DNA stability, and the way DNA interacts with
proteins to control gene expression. TCGA provides methylation chip data. There are two
main types of DNA methylation: 450K and 27K. Generally, 450K is the most used. The
methylation is mainly located on CpG sites. The methylation will regulate the expression
of the genes.
CpG site is a site on the DNA sequence with a base of C or G. Methylated cytosines
are primarily found at CpG sites. As for gene-promoter region. At present, there is no
unified expression of the gene-promoter region. Generally, we think that the transcription
starts site (TSS) of a gene is between 2 kb upstream and 500 bp downstream. CpG islands
are generally considered that the regions where CpG sites are significant. The overall
methylation level of CpG island regions is often low and frequently appears in the promoter
region and exon region of genes. The relationship between methylation and genes is that
hypermethylation in the promoter of a gene will downregulate the expression of its
downstream genes, which is mostly negatively correlated.
TCGA provides a wealth of clinical follow-up information, including medication, relapse,
age, survival, etc., which contains more than 100 variables. Commonly used clinical
information includes: 1) age; 2) gender; 3) stages; 4) time of relapse; 5) overall survival, 6)
race; and 7) ethnicity.

[19]

TCGA has a separate ID, also called barcode, for each patient, such as TCGA-020001. This ID is universal in the TCGA database. According to this ID, we can find the
same patient in different types of data, including clinical follow-up information.
Different sampling sites of patients have different codes; for example, 01 indicates
cancer tissue, 10 indicates adjacent tissue, 01 to 09 generally indicates tumor site, and 10
and above indicates normal control. Portion means different components of the same
organization. Analyte represents the type of molecule analyzed; D represents DNA. The
Center represents the detection center.
D. Algorithms and Methodology

Identification of the survival subtypes
We used Cox-PH regression to select survival-related variables through the
multivariate method. In the survival analysis, the Cox proportional hazard model was used
to select survival-related variables with a p-value that is less than 0.05 [4]. The optimal
cluster number k is estimated by calculating the Silhouette score and the plot. And we
clustered the obtained samples applying different clustering methods, such as K-means, Kmodes, and GMM (Figure 1). We used the survival package in R [46] to analyze the
survival difference among different survival risk subtypes in the TCGA KIRC dataset. We
use a “survdiff” function that calculates the difference in survival between the two subtypes
and plots a Kaplan-Meier curve with a log-rank p-value.
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Figure 1. Clustering samples by using three clustering methods.
Regarding the K-means clustering algorithm with multiple iterations, the data is
first randomly defined as K-centers, where K is the number of subtypes determined by
silhouette score. The basic K-means algorithm flow is as follows; for the samples of the
KIRC data, the sum of the squared error (SSE) is used as the objective function of
clustering, so the clustering results can also be measured among sample with different
variables.
𝑘

𝑆𝑆𝐸 = ∑ ∑ 𝑑𝑖𝑠𝑡(𝑥, 𝑐𝑖 )
𝑖=1 𝑥∈𝐶𝑖
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This represents the sum of center ci distances from sample x to cluster Ci; the
clustering result should cause SSE to reach the minimum value.
The Gaussian mixture model is a probabilistic clustering method that assumes that
all data samples x are generated by a mixture of k multivariate Gaussian distributions.
𝑘

𝑝(𝑥) = ∑ 𝛼𝑖 ∙ 𝑝(𝑥|𝜇𝑖 , ∑𝑖 )
𝑖=1

where 𝑝(𝑥|𝜇𝑖 , ∑𝑖 ) is the probability density function of the n-dimensional random vector
x following the Gaussian distribution.

𝑝(𝑥) =

1
𝑛

1
(𝑥−𝜇)𝑇 Σ−1 (𝑥−𝜇)

−
2
1𝑒

(2𝜋) 2 |∑|2

For discrete attribute data sets, calculating the cluster mean and the Euclidean
distance between points becomes inappropriate. As an extension of K-means, K-modes is
suitable for categorical attribute datasets.
Suppose there are n samples, m attributes are all discrete, and the number of clusters
is k, which are randomly determined k clustering centers; and Ci is a vector of length m.
When comparing the distance between each sample and k centers, this distance is the
number of mismatched attribute values. All samples are divided into clusters that minimize
the sum of all distances; after each sample is clustered, the clustering center is also redetermined and iterates in turn until each sample is clustered into k modes. Repeat the
above steps until the total distance no longer decreases and the final clustering result is
returned.
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Normalization procedure
We first applied rank normalization to each omics data. For a given omic, we
defined the input matrix 𝑀 = (𝑣1 , . . . , 𝑣𝑚 ) as a list of m sample vectors v, having n
features in each matrix. For a given sample vector 𝑣 = (𝑥1 , . . . , 𝑥𝑛 ), the function rank(xi)
represents the ranking of each feature xi in v (n represents the feature x as the highest value,
and 1 represents the feature x as the lowest value). vrank is defined by:

𝑣𝑟𝑎𝑛𝑘 = (𝑟𝑎𝑛𝑘(𝑥1 ), … , 𝑟𝑎𝑛𝑘(𝑥𝑛 )) ∙

1
𝑛

We then normalized 𝑀𝑟𝑎𝑛𝑘 = (𝑣𝑟𝑎𝑛𝑘1 , . . . , 𝑣𝑟𝑎𝑛𝑘𝑚 ) by computing the Pearson
correlation coefficient between each pair of samples.
𝑀𝑐𝑜𝑟𝑟 (𝑖, 𝑗) = 𝑑𝑝𝑒𝑎𝑟𝑠𝑜𝑛 (𝑣𝑟𝑎𝑛𝑘 𝑖 , 𝑣𝑟𝑎𝑛𝑘 𝑗 )

Thus, 𝑀𝑐𝑜𝑟𝑟 = {𝑀𝑐𝑜𝑟𝑟 (𝑖, 𝑗) | 𝑖, 𝑗 ∈ 𝑚} is an m×m matrix. Finally, for each sample
vector of 𝑀𝑐𝑜𝑟𝑟 = (𝑚1 , . . . , 𝑚𝑚 ), we again applied the rank normalization to the Pearson
correlation coefficient matrix, where corr is the Pearson correlation coefficient between
samples:

𝑚𝑟𝑎𝑛𝑘 = (𝑟𝑎𝑛𝑘(𝑐𝑜𝑟𝑟1 ), … , 𝑟𝑎𝑛𝑘(𝑐𝑜𝑟𝑟𝑛 )) ∙

𝑀𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 = (𝑚𝑟𝑎𝑛𝑘 1 , . . . , 𝑚𝑟𝑎𝑛𝑘 𝑚 )
New features selection

1
𝑛
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We selected the common samples from every single omics data, that is each sample
has all types of data utilized in clustering and classification. Then, each omic data was used
as a separate matrix for rank normalization. Then we computed the Pearson correlation
coefficient between every pair of samples. Rank normalization was applied again to the
Pearson correlation matrix. Thus, three input matrices were obtained. These three matrices
were input into the trained denoising autoencoder and PCA model to obtain new features
[17]. Through the R language survival package for univariate function for these features,
the features related to survival were selected. Finally, we selected individual features
related to survival, stacked them into a single matrix, and inputted the features in the
classifier (Figure 2).

Figure 2. New features selection and classification with multi-omics data.
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Denoising autoencoder construction
𝑂𝑀𝐼𝐶
For each input matrix 𝑀𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑
, we constructed a denoising autoencoder with

one hidden layer. A denoising autoencoder can be defined as a function 𝑓(𝑣) = 𝑣′, where
v is an input vector of size m, and 𝑠𝑖𝑧𝑒(𝑣′) = 𝑠𝑖𝑧𝑒(𝑣) = 𝑚. f is a function that encodes
and reconstructs m features by encoding m features into h hidden nodes and decoding to
restore h nodes to m features. This is done by encoding and decoding, so we define f by:
𝑓(𝑣) = 𝜎(𝑊′ ∙ 𝜎(𝑊 ∙ 𝑣 + 𝑏) + 𝑏′)

Transpose the decoded weight matrix W' into the encoded weight matrix transpose:
𝑊′ = 𝑊 𝑇 , which is referred to as “tied weights.” By optimizing the parameters of the
model, the average reconstruction error of the network is minimized. b and b' are two biases
vectors of sizes h and m, respectively. 𝜎 is a nonlinear activation function, such as the
sigmoid or tanh functions. The autoencoder uses the adam optimization algorithm to
iteratively find the best W, W', b, and b' minimize a loss function loss (v, v'). Adam uses
Momentum and Adaptive Learning Rates to converge faster. n is each training iteration,
and a specific percentage of the weight matrix coefficients is randomly set to 0 (decreasing)
to train the denoising autoencoder to reduce overfitting. We define 𝑍𝑂𝑀𝐼𝐶 as the transformed
𝑂𝑀𝐼𝐶
version of the 𝑀𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑
matrix. After training the autoencoder, the transformation Z of

v is given by 𝑓(𝑣) = 𝜎(𝑊 ∙ 𝑣 + 𝑏).
We used the ruta package and the Keras framework to build denoising
autoencoders. For each DAE, we used h = 100 (hidden nodes), the tanh as activation
function, the binary-crossentropy as loss function, sigmoid as output function, and the
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adam optimizer minimize the loss. Finally, we trained the autoencoders with 50 epochs
and a 50% dropout rate (Figure 3). We used the hidden nodes as new features from the
denoising autoencoder.

Figure 3. The network structure of the one hidden layer autoencoder.
To use the PCA method for dimension reduction, we selected the components with
Proportion of Variance (PoV) greater than 0.01. PoV means a part of variance as a whole.
This means that we use fewer components to represent 99% of the overall variance. On the
other hand, an alternative option is to select components from the PCA method as new
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features that are survival-related while p-values are less than 0.01 by using Cox-PH
analysis. For each omic, we built an individual model to select new features related to
survival. At this time, individual Cox-PH was used to select those features related to
survival from new matrices that were produced by dimension-reduction methods.
Identification of features related to survival
We selected the feature matrices obtained from the autoencoder: 𝑍𝑚𝑅𝑁𝐴, 𝑍𝑚𝑖𝑅𝑁𝐴,
and 𝑍𝑀𝑒𝑡ℎ𝑦𝑙𝑎𝑡𝑖𝑜𝑛 were the features related to survival. For each feature of these matrices, we
use a univariate Cox-PH model to select those with a log-rank p-value < 0.01. We stacked
the new features selected from each omics to get a new feature matrix, Zcom. We used the
univariate Cox-PH functions of the survival package in R to select features and compute
the p-values.
Classifiers construction
𝑀𝑒𝑡ℎ𝑦𝑙𝑎𝑡𝑖𝑜𝑛

𝑚𝑅𝑁𝐴
𝑚𝑖𝑅𝑁𝐴
For each normalized matrix—𝑀𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑
, 𝑀𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑
, and 𝑀𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 —we

applied the new feature matrix Zcom to the classification. We also stacked all the features
related to survival to construct a “multi-omics” SVM/RF model. Each model was built
using SVM/RF through 10-fold cross-validation. By predicting the survival risk subtype
of each sample, the accuracy of the clustering results was obtained.
E. Assumptions with Implied Limitations

Based on previous studies and known theories, we assumed that the clinical data of
cancer patients would show specific characteristics related to survival and certain
clustering patterns in different ages, disease stages, and other clinical data. This survival-

[27]

related clustering patterns may have a similar expression in multi-omics data, such as gene
expression, DNA methylation, and microRNA expression.
Using multi-omics data to verify the clustering results based on clinical data is very
promising to be able to obtain similar survival-related patterns between two types of
datasets. At the same time, the results may not show a perfect consistency between them,
as the selection of clinical data and the processing of multi-omics data may have further
need to improve. Therefore, based on existing processing methods and algorithms, results
verified by two kinds of data could be improved in advance.
IV. RESULTS

A. Brief Overview of Results

Our project obtained training and testing results related to the survival analysis by
clustering 534 samples in clinical data and classifying 317 multi-omics samples. The
samples were from the TCGA KIRC project: Three omics datasets and clinical dataset,
including mRNA, miRNA, DNA methylation, and clinical data of TCGA KIRC, were
downloaded using the TCGAbiolinks package in R programming tool. We applied a
multivariate Cox-PH method to select survival-related clinical variables, and age and stage
were selected as the features in the survival analysis. Using the Silhouette Coefficient (top
Silhouette score: 0.53 for k = 2), we determined that the optimal solution for the number
of clusters k related to survival was 2. By applying these variables, two clusters were
predicted by various clustering methods, such as K-means, K-modes, GMM, to indicate
different survival risks. K-fold cross-validation was used to evaluate the classification by
using SVM with linear kernels and RF; thus, to build a supervised classification model to
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verify whether there are common patterns with clinical data. In the classification, we
observed the best results when we labeled samples using the K-modes clustering results,
classified samples with the features obtained from the principal components selected by
the univariate Cox-PH method. We performed a classification algorithm using RF
validation in 10-fold cross-validation (Accuracy = 0.7503) while also with high sensitivity
and specificity. The classification result with p-value < 2e - 16 also proved that the result
had high reliability.
We further discussed which samples were misclassified among different omics
features. To summarize, while 161 samples were clustered in cluster 1, and 154 samples
were clustered in cluster 2 using the K-modes clustering method. Furthermore, 21 samples
were misclassified in Cluster 1, and 26 samples were misclassified in Cluster 2. We
compared the feature heat maps of multi-omics and labeled the misclassified samples. We
found that in the features heatmaps of mRNA and methylation, there were partial subclustering behaviors of the misclassified samples. In the features heatmaps of miRNA, the
sample distribution was more scattered.
B. Findings (Results) of the Clustering and Classification

We first downloaded the clinical data of KIRC patients from the TCGAbiolinks
package. We selected clinical variables that are significantly related to survival through
multivariate Cox-PH (Table 1), age and stage. By using the Silhouette Coefficient (top
Silhouette score: 0.53 for k = 2), we determined that the optimal solution for the number
of clusters k related to survival was 2, indicating that among all KIRC patients, two
subtypes related to survival were determined (Figure 4).
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Table 1. Log-rank p-value of multivariate Cox-PH for the TCGA KIRC patients’ clinical
data to select significantly related to survival analysis for clustering. By this method, age
(p-value = 7.37e - 05) and stage (p-value = 5.18e - 15) were selected as the variables to
cluster the cancer samples.
Coefficient
z
p-value
Gender

0.04900

0.228

0.819

Age

0.04176

3.964

7.37e - 05

***

Stage

0.71874

7.823

5.18e - 15

***

Race

-0.05056

-0.191

-0.191

Ethnicity

0.51587

1.394

0.163

Significant codes: 0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1

Figure 4. Silhouette score plot for the TCGA KIRC patients with clinical data that are
significantly related to survival analysis.
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Fewer dimensions mean less calculations, and fewer dimensions can allow the use
of algorithms that are not suitable for large dimensions. So, we use DAE, PCA, and
survival-related principal components. For DAE, we built a network with 100 hidden nodes
(h = 100) to limit each omic data to 100 new features. Then survival-related features were
computed. There were 52 survival-related features in DNA methylation, 25 survivalrelated features in mRNA, and 21 survival-related features in miRNA. To use the PCA
method for dimension reduction, components with Proportion of Variance greater than 0.01
were selected. There were 13 components selected in miRNA, and 11 components were
selected in mRNA and methylation separately. On the other hand, an alternative option is
to select components from the PCA method as new features that are survival-related while
p-values are less than 0.01 by using Cox-PH analysis. Here, there were 13 components in
miRNA and mRNA of each omic were selected that were survival related. And there were
11 components selected to be significantly related to survival in DNA methylation (Figure
5). For each omic, we built an individual model to select new features related to survival.
For this purpose, univariate Cox-PH was used to select the features that are related to
survival from new matrices that were produced by dimension-reduction methods. In
summary, there were 98 survival-related features selected by DAE from multi-omics data.
There were 35 principal components selected by PCA and 37 survival-related components
selected by PCA.
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number of features selected
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Figure 5. The number of features selected by different methods, DAE, PCA, and PCAsurv, separately.
Table 2. The classification in the 10-fold cross-validation was performed. The samples
were labeled by K-means clusters with new features obtained by DAE, PCA, and PCAsurv respectively. The samples were classified using random forest and SVM methods. The
results were obtained through a confusion matrix of classification.
Random forest

Support vector machine

DAE

PCA

PCA-surv

DAE

PCA

PCA-surv

Accuracy

0.5862

0.5397

0.5492

0.6143

0.6243

0.5598

Sensitivity

0.6986

0.6567

0.6687

0.6238

0.6437

0.5998

Specificity

0.4595

0.4077

0.4144

0.6036

0.6025

0.5146

Classification

0.0003

0.29

0.127

1.014e -

< 2e - 16

0.0052

p-value

13
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Table 3. The classification in the 10-fold cross-validation was performed. The samples
were labeled by GMM clusters with new features obtained by DAE, PCA, and PCA-surv
respectively. The samples were classified using random forest and SVM methods. The
results were obtained through a confusion matrix of classification.
Random forest

Support vector machine

DAE

PCA

PCA-surv

DAE

PCA

PCA-surv

Accuracy

0.627

0.6127

0.6302

0.6074

0.5958

0.636

Sensitivity

0.8036

0.7577

0.7823

0.7857

0.8486

0.7866

Specificity

0.3361

0.3739

0.3796

0.3137

0.1793

0.3880

Classification

0.344

0.8101

0.2461

< 2e - 16

< 2e - 16

0.113

p-value

Table 4. The classification in the 10-fold cross-validation was performed. The samples
were labeled by K-modes clusters with new features obtained by DAE, PCA, and PCAsurv respectively. The samples were classified using random forest and SVM methods. The
results were obtained through a confusion matrix of classification.
Random forest

Support vector machine

DAE

PCA

PCA-surv

DAE

PCA

PCA-surv

Accuracy

0.7481

0.7429

0.7503

0.7148

0.7296

0.7254

Sensitivity

0.7723

0.7785

0.7598

0.8833

0.9049

0.9243

Specificity

0.7229

0.7256

0.7403

0.1756

0.1689

0.0888

< 2e - 16

< 2e - 16

< 2e - 16

0.9999

0.9995

0.9999

Classification
p-value

Among these different algorithms(Tables 2–4), we selected K-modes for clustering,
PCA-surv for dimension reduction, and SVM for classification, respectively in 10-fold
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cross-validation, that produce an optimized model in terms of classification accuracy
(Accuracy = 0.7503) of our survival- specific subtypes prediction. The result of p-value <
2e - 16 also proves that the result had high reliability.
We compared the performance of the two patient clusters in the survival patterns
because the results obtained by K-modes clustering in multi-omics classification performed
best. We observed that the Kaplan-Meier plot that the two groups of patients have
significant differences in survival analysis (p-value < 0.0001), which shows that our
clustering can divide KIRC patients into high survival risk and low survival risk subtypes
(Figure 6).

Figure 6. Survival profile with Kaplan-Meier plot of two subtypes for the TCGA KIRC
patients.
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Stage distribution in each cluster
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Figure 7. According to the results of K-modes clustering, the samples of different groups
are distributed at different stages.
By comparing the distribution of the two groups of patients in different clinical data,
we found that Cluster 1, which indicated the high survival risk subtype, were more
distributed in stages 2–4. In Cluster 2, almost all the samples were distributed in the first
stage, which indicated low survival-risk subtypes (Figure 7). We then discussed the role
that stages played in clustering alone. We divided Stage 1 into an early stage, and we
divided Stages 2–4 into an advanced stage. We used this as evidence for classification to
cross-validate the survival-related features obtained by applying multi-omics data. The
results obtained were very close to the best results obtained before (Table 5). We thought
that stages played a more prominent role in sample clustering than age.
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Table 5. The classification of samples labeled by K-modes clusters in the 10-fold crossvalidation, and the new features obtained by PCA-surv were classified in cross-validation.
The results were validated using the RF method. The results were obtained through a
confusion matrix.
Random forest
PCA-surv
Accuracy

0.7545

Sensitivity

0.7419

Specificity

0.7667

Classification

< 2e - 16

p-value

We then further explored the misclassification of samples in each cluster. We got
the following results:
In Cluster 1,
•

1 sample in Stage 1 was misclassified,

•

7 samples in Stage 2 were misclassified,

•

8 samples in Stage 3 were misclassified,

•

5 samples in Stage 4 were misclassified.

In Cluster 2,
•

25 samples in Stage 1 were misclassified,

•

1 sample in Stage 4 was misclassified.

To summarize, 21 samples were misclassified in Cluster 1, and 26 samples were
misclassified in Cluster 2.
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Finally, we compared the features heatmaps of multi-omics and labeled the
misclassified samples. We can find that in the features heatmaps of mRNA and DNA
methylation (Figures 8 and 9), there were partial sub-clustering behaviors of the
misclassified samples. In the features heatmaps of miRNA (Figure 10), the sample
distribution was more scattered.
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mRNA features

Sample index
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mRNA features

Sample index
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Figure 8. The heatmaps of mRNA features with samples that were misclassified in each
cluster. a) The heatmap of Cluster 1 with mRNA features obtained by the PCA-surv method,
and b) the heatmap of cluster 2 with mRNA features obtained by the PCA-surv method. 15) The sample index for each misclassified sample in the sub-cluster.
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Figure 9. The heatmaps of DNA methylation features with samples that were misclassified
in each cluster. a) The heatmap of Cluster 1 with methylation features obtained by the PCAsurv method, and b) the heatmap of Cluster 2 with methylation features obtained by the
PCA-surv method. 1-5) The sample index for each misclassified sample in the sub-cluster.
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miRNA features

Sample index
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miRNA features

Figure 10. The heatmaps of miRNA features with samples that were misclassified in each
cluster. a) The heatmap of Cluster 1 with miRNA features obtained by the PCA-surv
method, and b) the heatmap of Cluster 2 with miRNA features obtained by the PCA-surv
method.
V. CONCLUSION AND DISCUSSION

A. Brief Summary of the Research

We tested our pipeline on Kidney Renal Clear Cell Carcinoma (KIRC) cancer from
the TCGA database. We integrated KIRC clinical data along with gene expression, DNA
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methylation and miRNA expression datasets in the pipeline. The data for analysis was
downloaded using TCGAbiolinks package in the R programming language.
In this project, 534 samples of clinical data and 317 samples of KIRC were obtained
from TCGA for integrating and pre-processing. A total of 315 samples with all types of
data were clustered into 2 clusters using K-means, GMM, and K-modes clustering methods.
We used rank normalization to pre-process the multi-omics data and inputted the features
into dimensional reduction models to select new features that were related to survival. To
reduce the dimension of the multi-omics datasets, we tested different algorithms such as
denoising autoencoder, Principal components analysis (PCA) and PCA-surv. For the
classification purpose, we tested two different machine learning methods, such as, support
vector machine (SVM) and random forest. Among these different algorithms, we selected
K-modes, PCA-surv, and SVM for clustering, dimension reduction and classification,
respectively, that produce an optimized model in terms of classification accuracy of our
survival-risk-specific subtypes.
B. Findings (Results) and Implications

Through Cox-PH, we selected age and stage as two features related to survival. By
using the Silhouette Coefficient, we determined that the optimal number of clusters of k is
2. After comparing Kaplan Meier-plot, these two subtypes were significantly different in
survival analysis (p-value < 0.0001). We define these two subtypes as the high-risk group
and the low-risk group.
We compared the autoencoder with the PCA method and performed two different
treatments on the principal components obtained by the PCA method. For each DAE, we
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used h = 100 (hidden nodes). Finally, we trained the autoencoders on 50 epochs with a 50%
𝑂𝑀𝐼𝐶
dropout rate. We defined 𝑍𝑂𝑀𝐼𝐶 as the transformed version of the 𝑀𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑
matrix. To

use the PCA method for dimension reduction, we selected components with Proportion of
Variance greater than 0.01 and survival-related principal components from the PCA
method as new features while p-values are less than 0.01 by using Cox-PH analysis. For
each omic, we built an individual model to select new features related to survival. In this
step, individual Cox-PH was used to select features that are related to survival from new
matrices that were produced by dimension-reduction methods. New matrices containing
98, 35, and 37 features were obtained.
Through classification, the best accuracy value we obtained for different validation
methods was 0.7503. This showed that samples with survival-related principal components
could be more accurately classified in classification. At the same time, RF also performed
better than SVM in classification.
We also discussed the results of different risk subtypes under unique clinical data.
The results showed that stages play a more prominent role in clustering analysis than age.
In addition, among the misclassified samples, 21 samples were misclassified in Cluster 1,
and 26 samples were misclassified in Cluster 2. Finally, we compared the features
heatmaps of multi-omics and labeled the misclassified samples. We found that in the
features heatmaps of mRNA and methylation, there were partial sub-clustering behaviors
of the misclassified samples. In the features heatmaps of miRNA, the sample distribution
was more scattered.
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C. Research Analysis of Findings

This was a preliminary exploration of the integration of clinical data and multiomics data to find differences in survival risks in KIRC samples. Survival Clustering
provides a new idea, and on this basis, we can consider more omics data and clinical data.
Here, we have three omics datasets and one clinical dataset. We clustered two subtypes
with significant differences in survival risk and applied multi-omics data to indicate risk
subtypes through cross-validation. We can use different clinical data sets to determine the
risk subtypes of KIRC patient samples. We need a more complete method to pre-process
and select clinical data sets to consider more clinical data and prognostic signatures. Finally,
through DAE and PCA, we performed dimensionality reduction and feature selection on
multi-omics data, and we used more concise data to represent the characteristics of highdimensional data. This can pre-process more omics data into verifiable feature matrices.
D. Reliability and Validity of Survival-Related Subtypes

By studying previous research results, we understand that the integration of multiomics research plays an important role in the clustering of cancer patients. We expect the
integration of multi-omics data to verify the characteristics of survival analysis in clinical
data. We hypothesize that there are similar survival characteristics in clinical data and
multi-omics data. We can select variables closely related to survival through Cox-PH and
divide the cancer samples into different survival risks by clustering type.
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E. Summary of Academic Study

We proposed a survival-related prognostic integration pipeline. Through Cox-PH
analysis, we selected the clinical data of KIRC patients as survival-related clustering
indicators, which gave overall significant p-values. We used the Silhouette Coefficient to
determine the optimal number k of clusters. We obtained three omics datasets, including
mRNA, miRNA, and methylation, and clinical data of the TCGA KIRC project from the
Genomics Data Commons web portal (https://portal.gdc.cancer.gov); the data was
downloaded by the TGCAbiolinks package in the R programming language.
Using survival analysis on clinical data, KIRC patients were divided into two
survival subtypes. We then established a supervised classification model using the DAE
and the PCA. For each omic, we built an individual model to select new features related to
survival. At this time, individual Cox-PH was used to select features that are related to
survival from new matrices that were produced by dimension-reduction methods. These
features were then classified by the clusters inferred by the clinical survival-related
variables. K-fold cross-validation was utilized for classification by using SVM with linear
kernels and RF to build a supervised classification model to verify whether there are
common patterns with clinical data. Accuracy, specificity, and sensitivity were used to
evaluate the results. A confusion matrix was used to combine these parameters to gain a
comprehensive view of the results.
Overall, we identified two subtypes of survival risk through cluster analysis. These
two subtypes have significant survival differences. We used the K-modes clustering
method to cluster KIRC samples into two different subtypes. We then used the DAE, PCA,
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and PCA-surv methods to perform feature screening with the processed three omics data.
We obtained matrixes containing 98, 35, and 37 new features, and we used the SVM/RF
classification model to perform 10-fold cross-validation, the classification results obtained
by the final RF method had the highest accuracy. Through classification, the best accuracy
we obtained among different classification methods was 0.7503.
Among the misclassified samples, 21 samples were misclassified in Cluster 1, and
26 samples were misclassified in Cluster 2. We found that in the features heatmaps of
mRNA and methylation, there were partial sub-clustering behaviors of the misclassified
samples.
F. Limitations of the Theory or Method of Research

Although we can attain better verification results through this method, as it relates
to the selection of clinical data related to survival, the method we used is still relatively
straightforward, so there may be some data overfitting or some data are not correctly
selected. We can consider as much clinical data, prognostic signatures, and biochemical
indicators as possible. More normalization methods to integrate data belonging to different
ranges into data of similar ranges could be considered, as the selection of data is not
optimized enough. In addition, as it relates to dimensionality-reduction processing and
feature selection of multi-omics data, no other methods were considered, resulting in some
methods that had deviations in the selection of different omics data, so that some data were
selected for many features while other data had few or no features. Therefore, there are still
some shortcomings in data processing and algorithm optimization.
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G. Future Study

In future research, we will try to use more clinical data, prognostic signatures, and
biochemical indicators as the basis for clustering. We will use more normalization methods
to process the data to a better selection to choose more comprehensive and reliable data.
We hope to consider more data in survival analysis so that survival-related features can be
more comprehensively applied to survival clustering algorithms.
In addition, as it relates to data processing of multi-omics, we expect to be able to
refer to more data-processing methods, learn more deep-learning methods and neural
network algorithms, and select new features related to survival after dimensional-reduction
processing.
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